Yes, immunohistochemistry (IHC) should be performed on both breast lesions when multifocal or multicentric disease is present.
In cases of multifocal and multicentric breast tumors, all lesions must be biopsied and tested for biomarkers including ER, PR, and HER2 status 1. This is a mandatory recommendation from the 2019 ESMO guidelines, which explicitly states that "in case of multifocal and multicentric tumours, all lesions should be biopsied" with core needle biopsy being the preferred method 1.
Why Both Lesions Require IHC Testing
The rationale for testing all lesions stems from the well-documented phenomenon of tumor heterogeneity:
- Different lesions can harbor distinct biological profiles: Even when both lesions appear to be infiltrating ductal carcinoma morphologically, they may express different hormone receptor and HER2 status 1
- Treatment decisions depend on the most aggressive biology: If one lesion is ER-positive/HER2-negative and the other is triple-negative, this fundamentally changes systemic therapy recommendations
- Prognostic staging incorporates biological markers: The AJCC 8th edition TNM staging system includes ER, PR, HER2, and grade as prognostic factors, requiring complete characterization of all disease 1
Practical Implementation Algorithm
Step 1: Core Needle Biopsy of Both Lesions
- Obtain at least 2-3 cores from each lesion under US or stereotactic guidance 1
- Place a marker (surgical clip or carbon) in each biopsied lesion to ensure correct site identification 1
Step 2: Perform Complete IHC Panel on Both Specimens
- ER status (using standardized methodology like Allred score or H-score) 1
- PR status 1
- HER2 status (IHC and/or ISH per ASCO-CAP guidelines) 1, 2
- Ki67 labeling index if standardized assay available 1
Step 3: Verify Results if Discordant
- If ER/PR/HER2 results differ between lesions, retest on surgical specimens to account for tumor heterogeneity 1
- If initial biopsy shows negativity for ER/PR and HER2, mandatory retesting on surgical specimen is advisable 1
Critical Caveats
Fixation quality matters: Core biopsies allow better-controlled fixation compared to surgical specimens, providing safer antigen preservation for IHC 1. Samples should be fixed in 10% neutral buffered formalin for 6-72 hours 3.
Small biopsy limitations: If the amount of invasive tumor in the core biopsy is small, consider retesting on the excision specimen, particularly if the tumor is grade 3 or if there's morphologically distinct high-grade carcinoma in the resection specimen 2.
Reporting requirements: Each lesion should be reported separately with complete pathological information including histological type, grade, and all biomarker results to enable proper surrogate intrinsic subtype classification (Luminal A-like, Luminal B-like, HER2-positive, Triple-negative) 1.
The 2019 ESMO guideline provides Level I, Grade A evidence for this recommendation, making it the strongest possible evidence-based mandate in breast cancer management 1.